Immunitybio, inc. investor alert (nasdaq: ibrx): schubert jonckheer & kolbe llp investigating potential shareholder claims against the company's officers and directors for possible false statements

San francisco , nov. 19, 2024 /prnewswire/ -- schubert jonckheer & kolbe llp advises immunitybio, inc. investors that the firm is investigating potential legal claims relating to the company's unsuccessful efforts in 2023 to secure regulatory approval for its flagship product anktiva, designed to treat bladder cancer. current shareholders are encouraged to contact the firm.
IBRX Ratings Summary
IBRX Quant Ranking